Applied dna biotherapeutics subsidiary reports lineardna™ platform development milestone: first successful administration of lineardna in vivo via lipid nanoparticles (lnp)

Stony brook, n.y.--(business wire)---- $apdn #lnp--applied dna sciences, inc. (nasdaq: apdn) (the “company”), a leader in pcr-based dna technologies, today announced that linearx, the company's majority-owned biotherapeutics subsidiary, has for the first time successfully administered and expressed a lineardna-lnp construct in mice via routine intramuscular (im) injection without the concurrent use of electroporation (ep) that utilizes electrical pulses to deliver dna to target cells. the company believes tha
APDN Ratings Summary
APDN Quant Ranking